MedImmune in-licenses 2 cancer technologies

MEDI received exclusive worldwide rights to two cancer technologies: Human Aspartyl (Asparaginyl) Beta-Hydroxylase (HAAH) enzyme targeting technology from Panacea (Rockville, Md.) and technology targeting PC-cell-derived growth factor (PCDGF) from A&G Pharmaceutical (Baltimore, Md.). MEDI made equity investments in both companies, and will pay upfront fees and royalties. ...